The purpose of this study is to evaluate a new formulation of dulaglutide (study drug)
administered under the skin as one injection using a single dose pen compared to three
injections using a pre filled syringe.
This study will evaluate how much of the study drug enters the body and how long it takes the
body to get rid of it. Information about any side effects that may occur will also be
collected.
The study will last about 84 days, including screening and will require overnight stays in
the clinical research unit (CRU).